China NMPA Inspection - Qingdao Runde Biotechnology Co., Ltd. - July 28, 2017

The National Medical Products Administration (NMPA), operating under its regulatory mandate for drug and cosmetic supervision in China, issued a public notification on July 28, 2017, announcing a "Supervision and Inspection" pertaining to Qingdao Youdu Biotechnology Co., Ltd. This announcement indicates that the company was formally subjected to regulatory scrutiny by the NMPA, which is responsible for ensuring the quality and safety of pharmaceutical products and cosmetics within the country. The published record, identified by the index number JGXX-2020-10001, serves as an official confirmation of the regulatory body's engagement with Qingdao Youdu Biotechnology.

However, the provided document is limited to being a notification of this activity. It does not contain critical details such as the specific dates on which the inspection was conducted. Crucially, the notification also refrains from disclosing any main violations or significant issues that may have been identified during the inspection process. Consequently, there is no information provided regarding any required corrective actions or compliance measures that Qingdao Youdu Biotechnology Co., Ltd. would need to implement following the regulatory assessment. The document primarily functions as a record of regulatory intent rather than a detailed inspection report, thus lacking specific findings or prescribed follow-up actions.